论文部分内容阅读
应用国产米托蒽醌为主的联合化疗方案治疗恶性淋巴瘤１５例，其中低度恶性４例、中度恶性７例、高度恶性４例；男９例，女６例；临床分期：Ⅱ期３例、Ⅲ期８例、Ⅳ期４例；初治１０例、复治５例．总有效率８６７％，其中初治病人１０例，ＣＲ５例，ＰＲ４例；复治病人５例，ＣＲ２例，ＰＲ２例．主要毒性反应为骨髓抑制，以白细胞减少为突出．消化道反应多为轻度，未见心脏毒性、肝功能损害及脱发．结果表明：米托蒽醌对低、中、高度恶性病例及难治性恶性淋巴瘤均有较好疗效，且毒性反应轻，是一有前途的抗肿瘤药物．
The use of domestic mitoxazole-based combination chemotherapy regimen in the treatment of malignant lymphoma in 15 cases, including 4 cases of low-grade malignancy, 7 cases of moderate malignancy, and 4 cases of high malignancy; 9 males and 6 females; clinical staging: Phase II 3 cases, 8 cases of stage III, 4 cases of stage IV; 10 cases of initial treatment, 5 cases of retreatment. The total effective rate was 86.7%, including 10 cases of untreated patients, 5 cases of CR, 4 cases of PR, 5 cases of retreatment, 2 cases of CR, 2 cases of PR. The main toxicity was myelosuppression, which was highlighted by neutropenia. Gastrointestinal reactions were mostly mild, no cardiac toxicity, liver damage, and hair loss. The results showed that mitoxantrone has good curative effect on low-, middle-, high-grade malignant cases and refractory lymphomas. It has a mild toxicity and is a promising anti-tumor drug.